Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild‐type and D79N α2A‐adrenoceptor transgenic mice

We investigated the cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild‐type and D79N α2A‐adrenoceptor mice. The in vitro pharmacology of these agonists was determined at recombinant (human) α2‐adrenoceptors and at endogenous (dog) α2A‐adrenoceptors. In wild‐type mice, rilmenidine, moxonidine (100, 300 and 1000 μg kg−1, i.v.) and clonidine (30, 100 and 300 μg kg−1, i.v.) dose‐dependently decreased blood pressure and heart rate. In D79N α2A‐adrenoceptor mice, responses to rilmenidine and moxonidine did not differ from vehicle control. Clonidine‐induced hypotension was absent, but dose‐dependent hypertension and bradycardia were observed. In wild‐type mice, responses to moxonidine (1 mg kg−1, i.v.) were antagonized by the non‐selective, non‐imidazoline α2‐adrenoceptor antagonist, RS‐79948‐197 (1 mg kg−1, i.v.). Affinity estimates (pKi) at human α2A‐, α2B‐ and α2C‐adrenoceptors, respectively, were: rilmenidine (5.80, 5.76 and 5.33), moxonidine (5.37,